A Study of Lasmiditan (LY573144) Over Four Migraine Attacks
Status:
Completed
Trial end date:
2021-07-08
Target enrollment:
Participant gender:
Summary
The reason for this study is to see how effective and safe the study drug known as lasmiditan
is in the acute treatment of 4 migraine attacks with or without aura.